<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04161547</url>
  </required_header>
  <id_info>
    <org_study_id>HA116201903/PRO I-MAD</org_study_id>
    <nct_id>NCT04161547</nct_id>
  </id_info>
  <brief_title>Tolerability and Pharmacokinetics of CSPCHA115 Capsules in Chinese Healthy Volunteers</brief_title>
  <official_title>A Phase I, Ascending Multiple-dose Clinical Trial of CSPCHA115 Capsules to Evaluate the Tolerability and Pharmacokinetics in Chinese Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, single-center, double-blind, ascending multiple-dose, placebo-controlled study
      to evaluate the tolerability and pharmacokinetics of CSPCHA115 capsules in Chinese healthy
      volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 20, 2019</start_date>
  <completion_date type="Anticipated">April 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 27, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and incidence of subjects with Adverse Events (AEs)</measure>
    <time_frame>12 days after drug administration</time_frame>
    <description>To evaluate the safety and tolerability after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically significant symptoms abnormalities</measure>
    <time_frame>10 days after drug administration</time_frame>
    <description>To evaluate the safety and tolerability after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically significant vital sign abnormalities</measure>
    <time_frame>10 days after drug administration</time_frame>
    <description>To evaluate the safety and tolerability after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically significant physical examination abnormalities</measure>
    <time_frame>10 days after drug administration</time_frame>
    <description>To evaluate the safety and tolerability after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically significant laboratory abnormalities</measure>
    <time_frame>10 days after drug administration</time_frame>
    <description>To evaluate the safety and tolerability after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically significant electrocardiograms (ECGs) abnormalities</measure>
    <time_frame>10 days after drug administration</time_frame>
    <description>To evaluate the safety and tolerability after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum observed concentration (Tmax)</measure>
    <time_frame>Day 1(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours); Day 5(Pre-dose); Day 6(Pre-dose); Day 7(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours) after drug administration</time_frame>
    <description>To evaluate the pharmacokinetics after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed concentration (Cmax)</measure>
    <time_frame>Day 1(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours); Day 5(Pre-dose); Day 6(Pre-dose); Day 7(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours) after drug administration</time_frame>
    <description>To evaluate the pharmacokinetics after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time 0 to 24h (AUC0-24h)</measure>
    <time_frame>Day 1(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours); Day 5(Pre-dose); Day 6(Pre-dose); Day 7(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours) after drug administration</time_frame>
    <description>To evaluate the pharmacokinetics after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax at steady state (Tss max)</measure>
    <time_frame>Day 1(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours); Day 5(Pre-dose); Day 6(Pre-dose); Day 7(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours) after drug administration</time_frame>
    <description>To evaluate the pharmacokinetics after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax at steady state (Css max)</measure>
    <time_frame>Day 1(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours); Day 5(Pre-dose); Day 6(Pre-dose); Day 7(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours) after drug administration</time_frame>
    <description>To evaluate the pharmacokinetics after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmin at steady state (Css min)</measure>
    <time_frame>Day 1(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours); Day 5(Pre-dose); Day 6(Pre-dose); Day 7(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours) after drug administration</time_frame>
    <description>To evaluate the pharmacokinetics after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average concentration at steady state (Css av)</measure>
    <time_frame>Day 1(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours); Day 5(Pre-dose); Day 6(Pre-dose); Day 7(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours) after drug administration</time_frame>
    <description>To evaluate the pharmacokinetics after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC at steady state (AUCss)</measure>
    <time_frame>Day 1(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours); Day 5(Pre-dose); Day 6(Pre-dose); Day 7(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours) after drug administration</time_frame>
    <description>To evaluate the pharmacokinetics after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination half-life (t1/2)</measure>
    <time_frame>Day 1(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours); Day 5(Pre-dose); Day 6(Pre-dose); Day 7(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours) after drug administration</time_frame>
    <description>To evaluate the pharmacokinetics after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent clearance at steady state (CLss/F)</measure>
    <time_frame>Day 1(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours); Day 5(Pre-dose); Day 6(Pre-dose); Day 7(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours) after drug administration</time_frame>
    <description>To evaluate the pharmacokinetics after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution (Vz/F)</measure>
    <time_frame>Day 1(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours); Day 5(Pre-dose); Day 6(Pre-dose); Day 7(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours) after drug administration</time_frame>
    <description>To evaluate the pharmacokinetics after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fluctuation coefficient (DF)</measure>
    <time_frame>Day 1(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours); Day 5(Pre-dose); Day 6(Pre-dose); Day 7(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours) after drug administration</time_frame>
    <description>To evaluate the pharmacokinetics after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation ratio (Rac)</measure>
    <time_frame>Day 1(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours); Day 5(Pre-dose); Day 6(Pre-dose); Day 7(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours) after drug administration</time_frame>
    <description>To evaluate the pharmacokinetics after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Asthma; Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Cohort A1: CSPCHA115 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CSPCHA115 100 mg or placebo administered orally in the fasted state for 7 days.
Eight subjects will receive CSPCHA115
Two subjects will receive matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A2: CSPCHA115 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CSPCHA115 200 mg or placebo administered orally in the fasted state for 7 days.
Eight subjects will receive CSPCHA115
Two subjects will receive matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A3: CSPCHA115 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CSPCHA115 400 mg or placebo administered orally in the fasted state for 7 days.
Eight subjects will receive CSPCHA115
Two subjects will receive matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A4: CSPCHA115 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CSPCHA115 600 mg or placebo administered orally in the fasted state for 7 days.
Eight subjects will receive CSPCHA115
Two subjects will receive matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CSPCHA115 100 mg; Matching placebo 100 mg</intervention_name>
    <description>CSPCHA115 100 mg once daily in the fasted state for 7 days; Matching placebo 100 mg once daily in the fasted state for 7 days.</description>
    <arm_group_label>Cohort A1: CSPCHA115 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CSPCHA115 200 mg; Matching placebo 200 mg</intervention_name>
    <description>CSPCHA115 200 mg once daily in the fasted state for 7 days; Matching placebo 200 mg once daily in the fasted state for 7 days.</description>
    <arm_group_label>Cohort A2: CSPCHA115 200 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CSPCHA115 400 mg; Matching placebo 400 mg</intervention_name>
    <description>CSPCHA115 400 mg once daily in the fasted state for 7 days; Matching placebo 400 mg once daily in the fasted state for 7 days.</description>
    <arm_group_label>Cohort A3: CSPCHA115 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CSPCHA115 600 mg; Matching placebo 600 mg</intervention_name>
    <description>CSPCHA115 600 mg once daily in the fasted state for 7 days; Matching placebo 600 mg once daily in the fasted state for 7 days.</description>
    <arm_group_label>Cohort A4: CSPCHA115 600 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 ≤ age ≤ 45 years old, male or female;

          -  Bodyweight≥45.0 kg (female) or 50.0 kg (male), 19 kg/m^2 ≤ Body Mass Index（BMI ）≤ 26
             kg/m^2;

          -  The female subjects are not during pregnancy or lactation; the male subjects have no
             sperm donation plan from the signing of the informed consent form to 1 month after the
             completion of the study. The subjects and their partners agree to use effective
             non-hormonal contraceptives (such as condoms, drug-free IUDs, etc.) from the day
             signing the informed consent form to 1 month after the completion of the study, or had
             taken permanent contraceptives (such as bilateral tubal ligation, vasectomy, etc.);

          -  Subjects voluntarily sign the informed consent form, and are able to complete the
             trial according to the protocol;

        Exclusion Criteria:

        Those who conform to one of the following provisions shall not be included in the group;

          -  A clear history of neurological or mental disorders (including seizures, dementia,
             depression or biphasic affective disorders, etc.); immunodeficient or
             immunosuppressive diseases, malignant tumor diseases; cardiovascular, liver and
             kidney, endocrine, respiratory, blood, digestive system and other chronic diseases;

          -  Subjects who underwent large surgical operations within 6 months before signing the
             informed consent (such as coronary artery bypass grafting, hepatorenectomy,
             nephrectomy, gynecological surgery, etc.), and those with acute neurological,
             digestive, respiratory, circulation, endocrine, blood and other systemic diseases
             within 3 months before signing the informed consent form may affect the absorption,
             distribution, metabolism and excretion of drugs;

          -  Subjects with allergic constitutions, or who are allergic to more than 1 drug, or had
             other known serious allergic reactions;

          -  Subjects who did not meet the health criteria during the screening period, including
             abnormal vital signs; QTc interval ≥ 450 ms (male) or 470ms (female), prolongation of
             QTc interval, or other abnormal clinical significance of electrocardiogram (ECG); the
             results of physical examination, laboratory examination and so on are abnormal and
             have clinical significance.

          -  One of hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (Anti-HCV),
             human immunodeficiency virus antibody (Anti-HIV) and Treponema pallidum antibody
             (Anti-TP) was positive;

          -  Any prescription drugs, non-prescription drugs, biological products, the Chinese
             patent medicines, herbs, vitamin dietary supplements, and health-care products (other
             than external use), oral long-acting contraceptives or embedded long-acting
             contraceptives were used regularly within 2 weeks before the signing of the informed
             consent form;

          -  A history of alcoholism, or alcohol test positive at screening;

          -  The average daily smoking volume was more than 5 within 6 months before signing the
             informed consent form;

          -  Drug abuse within 1 year before signing the informed consent form, or urine test
             positive for drugs at screening;

          -  Subjects who were accustomed to excessive caffeine drinks or foods that may affect
             drug metabolism within 4 weeks prior to the signing of the informed consent form;

          -  Subjects who lost blood or donated more than 200 ml within 8 weeks before signing the
             informed consent form, or who planned to donate blood within 1 month after the
             completion of the study;

          -  Subjects who plan to undergo surgery during the trial period, or those who plan to
             take part in strenuous exercise during the trial period;

          -  Subjects who are participating in other clinical trials, or who have participated in
             clinical trial about any other drugs or devices within 3 months before signing the
             informed consent form;

          -  Not suitable for this clinical trial judged by the investigators.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xuefang Xia</last_name>
    <role>Study Director</role>
    <affiliation>Department of Medicine, CSPC Clinical Development Division</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xuefang Xia</last_name>
    <phone>0311-67808812</phone>
    <email>xiaxuefang@mail.ecspc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kun Lou</last_name>
    <phone>0311-67808817</phone>
    <email>loukun@mail.ecspc.com</email>
  </overall_contact_backup>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 29, 2019</study_first_submitted>
  <study_first_submitted_qc>November 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2019</study_first_posted>
  <last_update_submitted>November 10, 2019</last_update_submitted>
  <last_update_submitted_qc>November 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CSPCHA115</keyword>
  <keyword>Asthma</keyword>
  <keyword>CRTH2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

